Category: Amphetamine

  • Viloxazine (Qelbree) for ADHD

    Date:  June 28, 2021 Issue #:  1627 Summary:  The FDA has approved viloxazine extended-release capsules (Qelbree – Supernus) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. Viloxazine is the second selective norepinephrine reuptake inhibitor to be approved in the US for treatment of ADHD; atomoxetine (Strattera, and generics) was approved in 2002.